Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lumateperone deuterated - Intra-Cellular Therapies

Next Previous
Drug Profile

Lumateperone deuterated - Intra-Cellular Therapies

Alternative Names: ITI 1284; ITI-1284 ODT-SL

Latest Information Update: 15 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Intra-Cellular Therapies
  • Class Antidementias; Antidepressants; Antipsychotics; Behavioural disorder therapies; Fluorobenzenes; Mood stabilisers; Organic deuterium compounds; Piperidines; Pyrroles; Quinoxalines; Sleep disorder therapies; Small molecules; Tosyl compounds
  • Mechanism of Action Dopamine D2 receptor modulators; Glutamate modulators; Serotonin 5-HT2A receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Agitation; Generalised anxiety disorder; Psychotic disorders
  • Phase I Unspecified
  • No development reported Behavioural disorders; Dementia; Depressive disorders

Most Recent Events

  • 02 Apr 2025 Intra-Cellular Therapies has been acquired by Johnson & Johnson
  • 26 Mar 2025 Intra-Cellular Therapies completes a phase I pharmacokinetic trial (In volunteers) in United Kingdom (SC) (NCT06786286)
  • 21 Feb 2025 Phase-II clinical trials in Generalised anxiety disorder (Monotherapy) (Sublingual) prior to February 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top